Login to Your Account

Myriad, Biomarin Team Up for BRCA Testing in Phase III

By Catherine Shaffer
Staff Writer

Wednesday, October 2, 2013
Myriad Genetics Inc. will return for a repeat engagement of its Phase I collaboration with Biomarin Pharmaceuticals Inc. to deliver BRAC testing for Biomarin’s pivotal Phase III trials of BMN 673. BMN 673 is an oral poly ADP-ribose polymerase (PARP) inhibitor designed to kill BRCA-deficient cancer cells.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription